Author Affiliations: Departments of Pharmacy (Ms Diamantouros and Dr Bartle) and Medicine (Dr Geerts), Sunnybrook Health Sciences Centre, and Centre for Patient Safety (Dr Geerts), University of Toronto, Toronto, Ontario, Canada.
Oral vitamin K antagonists, such as warfarin, are among the most commonly prescribed and potentially dangerous classes of medications.1 For many high-risk drugs, such as warfarin, there is a strong link between patient knowledge about the medication and their safe use.2 For warfarin, provision of high-quality education improves compliance, increases time in the therapeutic range, and leads to a reduction in complications.3 Patients are largely educated about warfarin through written information sheets provided by their pharmacies. Therefore, it is critical that these sheets are both accurate and understandable. The objectives of this study were to assess the content (accuracy and completeness) and reading level of patient education sheets (PES) about warfarin provided to patients by community pharmacies in Ontario, Canada, and by pharmaceutical producers of this high-risk drug.
A reference standard for content was developed based on a formal survey completed by 27 members of the Thrombosis Interest Group of Canada, a national group of thrombosis professionals. Five different warfarin PES (A, B, C, D, and E in the Table), distributed by 98% of the 3742 community pharmacies in Ontario (population, 12 million) were compared with the reference standard. The reading level was assessed using 2 standardized instruments, the SMOG and Flesch-Kincaid scales, and compared with the grade 5 to 6 reading level recommended for written patient information.4 Three patient booklets (X, Y, and Z in the Table), distributed by the commercial producers of warfarin, were also evaluated.
Expert consensus identified 50 items that were rated as “essential” or “important” for patient education about warfarin. On average, the PES included only 63% of the recommended essential or important knowledge items (range, 22%-72%) (Table). On average, the sheets had 24 missing items, including the importance of laboratory monitoring or reference to the variable and individualized dose of warfarin required by different patients. None of the PES mentioned specific target ranges for the international normalized ratio (INR) value or the consequences of having an INR result above or below the target range. Only 1 PES mentioned a safe amount of alcohol that could be consumed or the advice to avoid binge drinking. The others recommended patients to avoid alcohol, an example of incorrect information that could lead to unnecessary lifestyle restrictions and could have an impact on adherence. The average reading level of the PES was grade 10 using the Flesch-Kincaid scale (grade 9 to ≥12) and grade 12 using the SMOG scale (grade 12 to 14). The mean word-to-content ratio of the PES was 67:1, meaning that for every 67 words of text, 1 relevant item was stated. The longer the document, the more likely it was to cover important content.
The 3 pharmaceutical patient booklets were generally of better quality, including an average of 69% of the essential or important items (range, 50%-81%) and missing an average of 15 items. These booklets also contained fewer incorrect or misleading statements than those distributed by the community pharmacies. The reading level of these booklets was grade 8 using the Flesch-Kincaid scale (range, grade 8-9) and grade 11 using the SMOG scale (range, grade 11-12). Their mean word-to-content ratio was 68:1.
The findings of this study reveal that patients prescribed warfarin are very likely to receive information sheets from community pharmacies that contain only 63% of the content important for its safe use as well as statements that experts believe are misleading or incorrect. Comprehension of these sheets is also limited by a reading level approximately 5 or 6 grade levels above that recommended for health information.4 The readability results found in this study are consistent with previous research reviewing drug-related patient education brochures,5 where the mean reading level was grade 11. In a study of warfarin therapy, more than half of patients were unable to comprehend health-related words at levels beyond grade 8,6 and an increased risk of bleeding and nonadherence has been reported in patients with low literacy.7,8
The major limitation of this study is the absence of a gold standard for content of warfarin information; however, we relied on consensus from experts to create a reference standard. Although we reviewed PES distributed by Ontario pharmacies, the results are likely generalizable, since many community pharmacies across the country use information sheets obtained from the same small number of drug information databases. Since the drug information programs were produced by 5 different American and European software companies, our findings likely apply to warfarin PES at least across North America.
Appropriate and accurate information about warfarin is critical in helping patients make educated health care decisions. We suggest that standardization of the content of patient information about warfarin, developed with input from anticoagulation specialists and presented in a manner that is understandable by the majority of patients taking this medication, is an important patient safety priority. This approach to patient education must also be considered for other high-risk medications including the new oral anticoagulants and other medications with a narrow therapeutic index.
Correspondence: Dr Geerts, Thromboembolism Service, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Room D674, Toronto, ON M4N 3M5, Canada (firstname.lastname@example.org).
Published Online: February 25, 2013. doi:10.1001/jamainternmed.2013.2781
Author Contributions:Study concept and design: Diamantouros, Bartle, and Geerts. Acquisition of data: Diamantouros. Analysis and interpretation of data: Diamantouros, Bartle, and Geerts. Drafting of the manuscript: Diamantouros and Geerts. Critical revision of the manuscript for important intellectual content: Diamantouros, Bartle, and Geerts. Statistical analysis: Diamantouros. Administrative, technical, and material support: Geerts. Study supervision: Bartle and Geerts.
Conflict of Interest Disclosures: Dr Bartle is the author of the warfarin information sheet for the Thrombosis Interest Group of Canada.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.